BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

RXRX at a glance

Recursion Pharmaceuticals (RXRX) is trading at $2.45, down 9.93% on the day. Its market value of $1.53B makes it the 2863rd largest of the 3753 companies we follow.

It is close to the bottom of its 52-week range ($2.44 to $5.24), 53.2% under the high. Holders are behind 41.2% over twelve months, and down 24.6% across the last three months.

On the chart it has slipped under both the 50-day ($3.72) and 200-day ($3.44) moving averages; RSI is 31, and the last 30 sessions moved at roughly 103% annualized volatility.

For the quarter ended Sep 2026 it reported $18.06M in revenue, up 262.3% from a year earlier, and a net loss of $119.04M.

4 analysts follow the stock and the average call is "buy". The mean target, $6.63, sits 170.6% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$2.50 / $2.51
Average price today$2.55
Volume29.88MAvg (90d) 22.19M
Turnover$76.24M
Turnover rate5.14%of shares outstanding
Volume ratio0.87vs. recent average pace
Day amplitude11.77%
Market cap$1.53B
Float market cap$1.42B
Shares outstanding580.95M
EPS (TTM)-$1.44
P/B1.68
Book value / share$1.46
Net profit (TTM)-$896.77M
Net assets$906.11M
30-day volatility103.2%annualized
Avg daily range (ATR)13.12%of price, 14 days
Max drawdown (1y)-50.6%-50.6% from 1y peak

Quote as of Nov 21, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

D
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

D
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

F
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

4 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 7.1 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability2.2
Momentum13.9
Financial health62.1
Analyst view64.4

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$6.63+170.6% vs. current price
Consensus ratingBuy4 analysts covering
Morningstar fair value$6.80Price is below fair value

Wall Street’s average 12-month target is $6.63, 170.6% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $6.80, so shares trade 63.9% below that estimate. On earnings multiple, it sits in the 67th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
-9.9%
1 week
-23.1%
1 month
-31.6%
3 months
-24.6%
6 months
-18.6%
Year to date
-40.1%
1 year
-41.2%
Day range
$2.44$2.76
52-week range
$2.44$5.24

Technical signals

Full technicals →
Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-30.0%Bearish
Price vs 50-day average-34.1%Bearish
Price vs 200-day average-28.9%Bearish
50-day vs 200-day50d above 200dBullish
RSI (14)31.0Bearish
MACD (12,26,9)-0.31Bearish
Bollinger band position2%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How RXRX ranks on BeStock

Market value#2851 of 3734
Closeness to 52-week high#3131 of 3724
Dollar volume today#1140 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

RXRX is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on RXRX.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on RXRX

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

RXRX stock: common questions

What is RXRX's latest share price?

$2.45 is the latest print for RXRX, a move of -9.93% against yesterday's close of $2.72. Today's low and high so far: $2.44 and $2.76.

What is RXRX worth in total?

Equity value comes to $1.53B at the current price. By that measure it is number 2863 of the 3753 names in our coverage.

Where does RXRX sit in its 52-week range?

The year's floor is $2.44 and the ceiling $5.24. Shares are 53.2% away from that ceiling.

Does RXRX send cash back through a dividend?

Our data shows no dividend paid by Recursion Pharmaceuticals over the trailing twelve months.

Do Wall Street analysts like RXRX?

Of 4 analysts, 50% say buy, 50% hold and 0% sell. Price targets average $6.63, with the most cautious at $5.90 and the most optimistic at $8.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top